

Special Issue

Novel Insights on Cancer Stem Cells

Message from the Guest Editor

Cancer stem cells (CSCs) or cancer-initiating cells are an aggressive subpopulation present in a range of 1/1000 to 5–10/100 in the tumor bulk of different cancer types, including thyroid cancer and colorectal cancer, respectively. It has been demonstrated that this subpopulation is endowed with high metastatic potential and characterized by high expression levels of efflux pumps, self-renewal capacity and therapy resistance. Standard treatments fail to effectively impair tumor growth because of the persistence of this small subpopulation. The development of innovative therapeutic approaches that specifically target CSCs is urgently needed. In this Special Issue entitled “Novel Insights on Cancer Stem Cells”, we encourage the submission of original research papers and reviews regarding the most recent advances focused on unravelling innovative therapeutic strategies targeting CSCs or mechanisms regulating CSC maintenance, epigenetic reprogramming and resistance to therapy.

Guest Editor

Dr. Veronica Veschi

Department of Surgical and Oncological Sciences, Università degli Studi di Palermo, Palermo, Italy

Deadline for manuscript submissions

closed (30 June 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/157765

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).